person · Reporting owner

KLITGAARD WILLIAM E

Disclosed activity across 3 companies

Tapewire entity: 49088
SEC CIK: 0001229874

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
OmniAb, Inc.AHPA · Entity 5294	Director	August 09, 2021	August 10, 2021
Zapata Quantum, Inc.ZPTA · Entity 6486	Director	May 01, 2026	May 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

OmniAb, Inc.

Report date August 09, 2021 · Filed August 10, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2021-08-09 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The reporting person owns 35,000 Class B Ordinary Shares which are convertible into Class A Ordinary Shares as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-257177). The Class B Ordinary Shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person owns 35,000 Class B Ordinary Shares which are convertible into Class A Ordinary Shares as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-257177). The Class B Ordinary Shares have no expiration date.

Zapata Quantum, Inc.

Report date May 01, 2026 · Filed May 07, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	176,348	Reported balance Holding disclosure · report date 2026-05-01 · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · Balance 176,348
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2033-07-31	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-05-01 · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · Balance Not disclosed F1: The stock options are fully executed and received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement"), dated as of September 6, 2023, by and among the Issuer, Tigre Merger Sub, Inc. and Zapata Computing, Inc. ("Private Zapata"), in exchange for an option to acquire 75,000 shares of common stock of Private Zapata.
Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2026-06-12	IndirectBy William E. Klitgaard Trust	Not disclosed	Reported balance Holding disclosure · report date 2026-05-01 · row 3 Amendment: may correct only part of an earlier disclosure. 1 source row Row 3 · Balance Not disclosed F2: The Notes mature on the one-year anniversary of the issuance date (subject to acceleration upon the occurrence of certain customary events of default or a change of control) and bear 10% per annum interest. The Notes convert automatically upon the Company's completion of a securities offering resulting in gross proceeds of at least $5 million. The Notes and Warrants were sold as units for which the total purchase price paid by the Reporting Person was $100,000. F4: The Reporting Person is the trustee for the William E. Klitgaard Trust.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2030-06-12	IndirectBy William E. Klitgaard Trust	Not disclosed	Reported balance Holding disclosure · report date 2026-05-01 · row 4 Amendment: may correct only part of an earlier disclosure. 1 source row Row 4 · Balance Not disclosed F3: At any time when a registration statement registering the resale of shares issuable upon exercise of the Warrants is not effective, the Warrants can be exercised cashlessly. The Notes and Warrants were sold as units for which the total purchase price paid by the Reporting Person was $100,000. F4: The Reporting Person is the trustee for the William E. Klitgaard Trust.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options are fully executed and received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement"), dated as of September 6, 2023, by and among the Issuer, Tigre Merger Sub, Inc. and Zapata Computing, Inc. ("Private Zapata"), in exchange for an option to acquire 75,000 shares of common stock of Private Zapata.

F2: The Notes mature on the one-year anniversary of the issuance date (subject to acceleration upon the occurrence of certain customary events of default or a change of control) and bear 10% per annum interest. The Notes convert automatically upon the Company's completion of a securities offering resulting in gross proceeds of at least $5 million. The Notes and Warrants were sold as units for which the total purchase price paid by the Reporting Person was $100,000.

F3: At any time when a registration statement registering the resale of shares issuable upon exercise of the Warrants is not effective, the Warrants can be exercised cashlessly. The Notes and Warrants were sold as units for which the total purchase price paid by the Reporting Person was $100,000.

F4: The Reporting Person is the trustee for the William E. Klitgaard Trust.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Syneos Health, Inc.

Report date September 28, 2023 · Filed September 28, 2023

Section 16 reporting ended · disclosed 2023-09-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2023-09-28 transaction · row 1 1 source row Row 1 · 2023-09-28 · Disposition to issuer · Disposed 7,370 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes.

F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals,

F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 08, 2025 Filed Oct 10, 2025 20:35 UTC	Zapata Quantum, Inc. ZPTA · Entity 6486	GrantStock Options (Right to Buy) · Derivative	1,000,000	$0.00 Strike: $0.08	$0.00	Disclosure SEC source: 0001079973-25-001590 · ownership.xml · derivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-10-08 F1 · derivative.exercise_date: The grant of stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The stock options shall vest in equal monthly increments over two years, with the first vesting date to occur on November 8, 2025, subject to continued service as a director of the Issuer on each applicable vesting date and the execution of the Issuer's Stock Option Agreement. Read SEC document
July 10, 2024 Filed Jul 12, 2024 22:18 UTC	Zapata Quantum, Inc. ZPTA · Entity 6486	GrantRestricted Stock Units · Derivative	75,000	$0.00	$0.00	Disclosure SEC source: 0001062993-24-013693 · form4.xml · derivative · entry 2 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into shares of common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units will vest in three equal installments, with 25,000 shares of common stock vesting on October 10, 2024, 25,000 shares of common stock vesting on January 10, 2025, and 25,000 shares vesting on the date of the 2025 annual meeting of the Issuer's stockholders. F2 · derivative.expiration_date: The restricted stock units will vest in three equal installments, with 25,000 shares of common stock vesting on October 10, 2024, 25,000 shares of common stock vesting on January 10, 2025, and 25,000 shares vesting on the date of the 2025 annual meeting of the Issuer's stockholders. Read SEC document
July 10, 2024 Filed Jul 12, 2024 22:18 UTC	Zapata Quantum, Inc. ZPTA · Entity 6486	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001062993-24-013693 · form4.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,348 Read SEC document
March 28, 2024 Filed Apr 1, 2024 13:26 UTC	Zapata Quantum, Inc. ZPTA · Entity 6486	GrantStock Option (Right to Buy) · Derivative	68,558	Not disclosed Strike: $3.80	Not disclosed	Disclosure SEC source: 0001062993-24-007523 · form4.xml · derivative · entry 2 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,558 Underlying: Common Stock · 68,558 shares Expires 2033-07-31 F3 · price: Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement"), dated as of September 6, 2023, by and among the Issuer, Tigre Merger Sub, Inc. and Zapata Computing, Inc. ("Private Zapata"), in exchange for an option to acquire 75,000 shares of common stock of Private Zapata at a purchase price of $3.47 per share. F2 · derivative.exercise_date: The option will become exercisable in equal annual installments over two years from July 3, 2023. Read SEC document
March 28, 2024 Filed Apr 1, 2024 13:26 UTC	Zapata Quantum, Inc. ZPTA · Entity 6486	GrantCommon Stock	126,348	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-007523 · form4.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,348 F1 · price: Received in connection with the business combination (the "Merger") of a wholly owned subsidiary of the Issuer with Zapata Computing, Inc. ("Private Zapata"). In accordance with a Note Exchange Agreement, dated March 28, 2024, by and among the Reporting Person, the Issuer and Private Zapata, at the effective time of the Merger, the Reporting Person exchanged an outstanding Senior Secured Promissory Note between the Reporting Person and Private Zapata, with an aggregate principal amount, together with then-outstanding interest, of $568,568.92, for 126,348 shares of common stock of the Issuer, at a conversion price of $4.50 per share. Read SEC document
September 28, 2023 Filed Sep 28, 2023 21:06 UTC	Syneos Health, Inc. SYNH · Entity 109360	Disposition to issuerClass A Common Stock	7,370	$0.00	$0.00	Disclosure SEC source: 0001209191-23-050773 · doc4.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2 · price: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3 · price: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time. Read SEC document
May 25, 2023 Filed May 30, 2023 21:15 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	4,863	$0.00	$0.00	Disclosure SEC source: 0001209191-23-032942 · doc4.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,370 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the 2024 annual meeting of stockholders but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
October 17, 2022 Filed Oct 18, 2022 21:06 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	2,507	$0.00	$0.00	Disclosure SEC source: 0001209191-22-053980 · doc4.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,507 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
May 25, 2022 Filed May 27, 2022 21:08 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	2,839	$0.00	$0.00	Disclosure SEC source: 0001209191-22-032638 · doc4.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,438 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
May 12, 2021 Filed May 14, 2021 21:13 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	2,364	$0.00	$0.00	Disclosure SEC source: 0001209191-21-032816 · doc4.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,599 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
May 27, 2020 Filed May 29, 2020 21:05 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	2,803	$62.43	$174,991.29	Disclosure SEC source: 0001610950-20-000104 · wf-form4_159078633611524.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,235 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
May 24, 2019 Filed May 29, 2019 20:06 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	4,122	$42.45	$174,978.90	Disclosure SEC source: 0001610950-19-000026 · wf-form4_155916037817395.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,432 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
May 24, 2018 Filed May 25, 2018 20:07 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	4,103	$0.00	$0.00	Disclosure SEC source: 0001610950-18-000022 · wf-form4_152727885795890.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,310 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
May 23, 2017 Filed May 24, 2017 20:11 UTC	Syneos Health, Inc. INCR · Entity 109360	GrantClass A Common Stock	2,693	$0.00	$0.00	Disclosure SEC source: 0001610950-17-000031 · wf-form4_149565665117344.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,207 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors. Read SEC document
March 01, 2017 Filed Mar 3, 2017 13:38 UTC	Syneos Health, Inc. INCR · Entity 109360	GrantClass A Common Stock	514	$0.00	$0.00	Disclosure SEC source: 0001229874-17-000003 · wf-form4_148854827517505.xml · nonDerivative · entry 1 KLITGAARD WILLIAM E · CIK 0001229874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514 F1 · shares: Represents and award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.